key: cord-0959606-7xotk6ju authors: Aggarwal, Ranjana; Sumran, Garima title: An insight on medicinal attributes of 1,2,4-triazoles date: 2020-07-27 journal: Eur J Med Chem DOI: 10.1016/j.ejmech.2020.112652 sha: 0d2240c23ff29fa0f0749879edfe1825208a534b doc_id: 959606 cord_uid: 7xotk6ju The present review aims to summarize the pharmacological profile of 1,2,4-triazole, one of the emerging privileged scaffold, as antifungal, antibacterial, anticancer, anticonvulsant, antituberculosis, antiviral, antiparasitic, analgesic and anti-inflammatory agents, etc. along with structure-activity relationship. The comprehensive compilation of work carried out in the last decade on 1,2,4-triazole nucleus will provide inevitable scope for researchers for the advancement of novel potential drug candidates having better efficacy and selectivity. Among the various azaheterocyclic systems, azoles, in general, and 1,2,4-triazoles in particular are the focus of renewed interest among organic and medicinal chemists since several novel hybrids with broader spectrum have been synthesized based on molecular hybridization approach [1] . Among the azoles, triazoles are the most stable compounds and are difficult to cleave. 1,2,4-Triazole having molecular formula C 2 H 3 N 3 Author: Phone: +91(1744)238734, +919896740740; Fax: +91(1744)238277 Email: ranjanaaggarwal67@gmail.com acts as isosteres of amide, ester and carboxylic acid. It may be formally derived from pyrazole by substitution of a carbon at position-4 by nitrogen atom. 1,2,4-Triazole exists in two tautomeric forms A and B in which 1H-1,2,4-triazole (A) is more stable than 4H-1,2,4-triazole (B) as depicted in Fig. 1 [2] . 2) [3, 4] . Some commercial plant protection fungicides contain the triazole moiety, such as prothioconazole, triadimefon, metconazole, propiconazole, tebuconazole, epoxyconazole, triadimenol and cyproconazole [5] . 1,2,4-Triazoles and their fused heterocyclic derivatives have been reported to possess a wide range of bioactivities such as neuroprotectant [6] , antioxidant [7] , antimalarial [8] , antileishmanial [9] , anti-urease [10] , antiviral [11, 12] , anticonvulsant [13] , cannabinoid CB1 receptor antagonists [14] , PDE4A inhibitors [15] and γaminobutyric acid-A (GABA-A) α-2, α-3 and α-5 containing receptor antagonists [16] . Moreover, they have applications in ionic liquids, corrosion inhibitors, agrochemicals, polymers, supramolecular and material science [17] [18] [19] [20] [21] . Owing to the mounting importance of 1,2,4-triazoles in emerging domains, it is envisaged to bring out a comprehensive review of this privileged framework from 2010 onwards on the medicinal profile. The emergence of multidrug-resistant pathogens impelled the researchers to develop novel broad spectrum triazoles having high impact, ease of administration and low toxicity to conquer the resistance. The triazole antifungal drugs potently act by inhibiting the activity of cytochrome P450-dependent enzyme, the lanosterol 14α- O R R 1 = CH 2 Cl; CF 2 Cl; CF 3 ; CH 2 CH 3 ; CH 2 CH 2 CH 3 ; CH(CH 3 ) 2 ; CH 2 (CH 2 ) 2 CH 3 ; CH 2 (CH 2 ) 3 CH 3 ; C(CH 3 ) 3 ; CH 2 (CH 2 ) 4 CH 3 ; CH 2 (CH 2 ) 5 [47] . SAR study revealed the significance of R group as shown in Fig. 5 . Most of the synthesized clinafloxacin-triazole hybrids 28 (MIC: 0.25-2 μg/mL) endowed with good antibacterial and antifungal activities were comparable or more potent than the reference drugs chloramphenicol, clinafloxacin and fluconazole [48] . SAR studies revealed that compound 28g with a 2,4-difluoro at phenyl ring exhibited most potent antimicrobial efficacy (MIC: 0.25-1 μg/mL) particularly against methicillinresistant Staphylococcus aureus (MRSA) among the tested compounds as displayed in Triazole-fused fluoroquinolones 33 with a functional Mannich-base moiety at the C-8 position (Fig. 6 ) exhibited considerable antibacterial activities [53] . Nalidixic acid based 1,2,4-triazolo [3,4-b] [1, 3, 4] thiadiazole derivatives 34 were evaluated for their antimicrobial activity against two Gram-positive bacteria (S. aureus and Bacillus subtilis), three Gram-negative bacteria (P. aeruginosa, E. coli and K. pneumoniae) and two fungi (A. niger and F. oxysporum) by Aggarwal et al [54] . SAR study revealed that compound was resistant to nalidixic acid [55] . Further study revealed that the compounds 35c and 36d (IC 50 (Fig. 7) possessed significant activities against the tested phytopathogenic bacteria, among which compound 42a was found to be most active and it was 12-fold more potent against Xanthomonas oryzae pv. oryzae with EC 50 value of 7.2 μg/mL than bismerthiazol (EC 50 : 89.8 μg/mL) [60] . In vitro antibacterial activity of 1,2,4-triazolo [3,4-b] [1, 3, 4] thiadiazoles 43a-h ( Fig. 7 ) indicated high activity towards both drug-sensitive and drug-resistant Gram-positive bacteria, which was up to 16 times more than ampicillin [61] . Thiouracil derivatives containing a triazolo-thiadiazole moiety 44a-l (Fig. 7 ) displayed good to potent activity against Bacillus amyloliquefaciens, S. aureus and B. subtilis [62] . Interestingly, compound 44d exhibited inhibitory activity against SecA ATPase. Barbuceanu et al reported the synthesis and antibacterial activity of mercapto-1,2,4-triazoles bearing diphenylsulfone 45 against S. aureus, B. cereus, E. coli, Enterobacter cloacae, Acinetobacter baumannii and P. aeruginosa [63] . Among them, one of the compounds having bromo diphenylsulfone moiety at position-3 and 3,4,5trimethoxyphenyl fragment at the nitrogen atom N-4 of triazole ring, exhibited the strongest action against B. cereus (MIC: 8 µg/mL) (Fig. 8) . coli and P. aeruginosa) and fungus (C. albicans) by Mange et al [64] . All synthesized compounds 46-47 (MIC: 3.125 μg/mL) were equipotent with standard drug ceftriaxone against S. aureus whereas compounds 46a and 47d were more potent (MIC: 3.125 μg/mL) than ceftriaxone against C. albicans. A series of 5-(2-aminothiazol-4-yl)-4-substituted phenyl-4H-1,2,4-triazole-3thiols 48 and 49 (Fig. 8) were synthesized and assessed for their antibacterial activity against S. aureus, B. subtilis, E. coli and P. aeuroginosa by Hassan et al [65] . SAR indicated that the compound 48g having phenoxy moiety at para-postion of the phenyl ring exhibited broad spectrum antibacterial activity (MIC: 0.5-1 µM) which was comparable to gentamicin and ciprofloxacin. Yang and Bao synthesized 1,2,4-triazole derivatives 50 bearing quinazolinylpiperidinyl moiety and N-(substituted phenyl)acetamide unit (Fig. 8 ) and evaluated them for their antimicrobial activities [66] . Compounds 50e, 50g, 50i, 50l and 50n (EC 50 : 34.5-47.5 μg/mL) had better bactericidal activity than control bismerthiazol (85.6 μg/mL) against phytopathogenic bacterium X. oryzae pv. oryzae. SAR study presented the significance of strongly electron-withdrawing substituents (such as 2,4-di-F, 3-F, 3-NO 2 , 3-COCH 3 , 2-NO 2 , 2-CF 3 and 4-COCH 3 ) and their positions on the benzene ring for enhancing antibacterial activity. 1,2,4-Triazole-pyrimidine hybrids 51a and 51b (MIC: 1.8-4.7 μM, Fig. 8 ) displayed excellent activity against S. aureus and E. coli [67] . Moreover, compounds 51a (MIC: 0.75 μg/mL) and 51b (MIC: 0.43 μg/mL) were found to be 10->1600 fold more effective than most clinically used antibiotics against MRSA strain. Coumarin-based 1,2,4-triazoles 52 and 53 ( Fig. 9 ) were tested for their in vitro antibacterial activity against four Gram-positive (S. aureus, MRSA, B. subtilis and M. luteus) and four Gram-negative bacteria (E. coli, Proteus vulgaris, Salmonella typhi and S. dysenteriae) and antifungal activity against C. albicans, Saccharomyces cerevisiae and A. fumigatus by Shi and Zhau [68] . It was proposed that incoorporation of triazole to coumarin enhanced the activity. The SAR of coumarin triazoles 52a-c and 53a-c (MIC: 1-32 μg/mL) indicated that the compounds with alkyl-substituent as spacer were more active than the analogues with aralkyl spacer 52d and 53d (MIC: 32-64 μg/mL). Further, bis-triazole 53 displayed better antimicrobial activity than mono-triazoles 52. Antimicrobial evaluation of bis-1,2,4-triazole derivatives 54 revealed that triazole derivative with 3,4-dichlorobenzyl group showed more potent antibacterial activity against B. proteus (MIC: 0.5 μg/mL) than standard drugs norfloxacin and chloramphenicol [69] . SAR study showed that dihalobenzyl groups are more helpful for increasing antibacterial and antifungal efficacy in comparison with the monohalobenzyl ones ( Fig. 9) . A series of isopropanol-bridged carbazole triazoles 55 ( Fig. 9 ) were evaluated for their antibacterial activity against E. faecalis, S. aureus and E. coli by Zhang et al [70] . Among them, compound 55a ( Fig. 9 ) exhibited highest potency against E. faecalis (MIC: 2 μg/mL) which might be due to intercalation into DNA. Among the α-triazolyl chalcones 56, compound 56a emerged as a promising candidate which exhibited excellent activity (MIC: 4 μg/mL) against MRSA and M. luteus than chloromycin ( Fig. 9 ) [71] . Anticancer chemotherapeutic agents can exert diverse action mechanisms such as cell cycle arrest, enzyme inhibitors, tubulin modulators, angiogenesis inhibitors, DNA intercalators and groove binders, transcription regulators and gene regulators etc. [72] . A large number of chemical entities having 1,2,4-triazole motifs have emerged as promising anticancer agents such as vorozole, letrozole, and anastrozole. Kinases are a class of enzymes that catalyze activation of many proteins by phosphorylation of mostly serine, threonine, or tyrosine amino acids. Deregulation of kinases may lead to growth of cancer. Kinase inhibitors are being explored as antitumor agents due to their target specific action. PIM kinase family (PIM-1, PIM-2 and PIM-3), a class of serine/threonine kinase, are key molecular targets for the development of selective inhibitors having therapeutics potential in cancer treatment. Martínez-González et al reported synthesis of a series of novel triazolo [4,3b] pyridazin-3-yl-quinoline derivatives 57 (Fig. 10 ) as PIM inhibitors [73] . Lead 11 ). Molecular mechanism of anticancer potential of 58a in PC-3 cells is revealed by reduction of EGFR, Akt phosphorylation and PI3K phosphorylation. [75] . Among these, compound 59a was documented to exhibit most potent inhibitory activity against VEGFR-2 (94% inhibition at 117 ng/mL) and anticancer activity against MCF-7 cancer cells with IC 50 values of 7.9 μg/mL than tamoxifen (IC 50 : 8.38 μg/mL). Docking studies showed that compound 59a binds to the active site of VEGFR-2 through H-bonds, arene-cation and hydrophobic interactions. In another study, a series of diarylurea derivatives bearing a triazole moiety 62 ( Fig. 13) were evaluated for antitumor activity [77] . The most potent compound 62i Shahzad et al synthesized a series of 3-mercapto-1,2,4-triazole analogues 69 and 3-mercapto-1,2,4-triazole carboxylic acids 70 (Fig. 15 ) as thymidine phosphorylase (TP) inhibitors [86] . Compounds 70b-g revealed a good inhibitory potential with IC 50 in the range of 43.86-163.43 μM and angiogenic potential of compound 70c was elicited using the chick chorionic allantoic membrane (CAM) assay. Eissa et al synthesized two set of triazoloquinoxalines 73 and 74 ( Fig. 16 ) and studied their cytotoxic activity against HepG2, Hep-2, and Caco-2 cancer cell lines [88] . Hou et al synthesized 1,2,4-triazole derivatives containing 1,4-benzodioxane fragment 77 (Fig. 17 ) and evaluated their methionine aminopeptidase type II (MetAP2) inhibitory activity in an enzyme assay [90] . From biological study of tested compounds it was observed that most of the compounds exhibited potent MetAP2 inhibitory effect and 77k most effectively inhibited the growth of HepG2 cells and MetAP2. Cui et al explored diaryl-1,2,4-triazole-caffeic acid hybrids as COX-2/5-LOX dual inhibitors for cancer therapy [91] . The anticancer SAR of hybrids 78 (Fig. 18) indicated that amide derivatives 78e-g with superior COX-2 inhibition activities were less potent (IC 50 : 16.37-26.14 μM) than ester derivatives (78d, IC 50 Song et al synthesized 4-N-nitrophenyl substituted amino-4H-1,2,4-triazole derivatives 86 (Fig. 20 ) as aromatase inhibitors [95] . SAR study revealed that the compounds containing substituted benzyl group on amine have improved aromatase inhibitory activities. Compound 86g was the most active one with an IC 50 of 9.02 nM. Bromodomain-containing protein 4 (BRD4), a transcriptional and epigenetic regulator, recognises acetylated lysine residues in histones and has been emerged as key Tubulin Wang antiproliferative agents [116] . Among these, the most active compound 121b was further evaluated against 60 human cell lines and exhibited significant antitumor activity against [117] . SAR study revealed that ortho-quinone moiety and presence of electron-rich aromatic ring at the C-6 position improved the cytotoxicity. [134] . A mechanistic study illustrated that compounds 146b and 148b induced apoptosis in MCF-7 cells. (Fig. 34) to screen their anticonvulsant activity [140] . Results indicated that compound 155c was found to be more selective in MES screen with an ED 50 [142, 143] . Compounds 162a-g showed better activity as compared to standard drug valproate. Results revealed that elongation of alkyl fragment from -C 2 H 5 to -C 4 H 9 at 4-position of 1,2,4-triazole increased the activity approximately 4-fold (from 152 mg/kg to 38.5 mg/kg), due to increase in the lipophilicity of the molecule. Chromatographic tests showed that analogues 162h and 162i with C 10 and C 12 alkyl chain, respectively lack anticonvulsant effect due to the inability to cross the blood brain barrier (BBB). (Fig. 36) and screened for their anticonvulsant and antidepressant activity by using MES and forced swimming test (FST) [149] . Compound 164a exhibited most potent antidepressant activity and higher efficacy than the reference drug fluoxetine. SAR study revealed that compounds 164b and 164c having an n-pentyl and a hexyl chain attached to the core quinolinone fragment, respectively showed the highest anticonvulsant activities and provided 100% protection at the dose of 100 mg/kg. Goma (CVB3) [12] . In this study, compounds 196a and 196b (Fig. 40) [174] . Nine quinoxaline derivatives were prepared and evaluated for their antiviral activity against hepatitis C virus (HCV), hepatitis B virus (HBV), HSV-1, and human cytomegalovirus HCMV by El-Zahabi [175] . The in vitro screening data indicated that the pyridinyl triazole derivative 198 (Fig. 40 ) exhibited highly potent activity against HCMV with IC 50 of <0.05 μM than that of reference drug ganciclovir (IC 50 : 0.59 μM). In addition, it also exhibited eleven times higher SI (>3000 μM) against HCMV than ganciclovir (SI >256 μM). Massari et al via hit-to-lead optimization studies identified two hybrid molecules 199 and 200 (Fig. 40) , having triazolopyrimidine and cycloheptathiophene scaffolds, as potent Flu polymerase PA-PB1 subunits inhibitors [176] . Along with PA-PB1 interaction inhibitor, 199 also exhibited broad anti-Flu activity with no cytotoxicity. 3 nM) as a highly potent in vitro inhibitor of P. falciparum 3D7 strain. Notably, compound 210a exhibited 55% oral bioavailability in CD-1 mice and in vivo activity with the ED 50 of 12mg/kg in nonmyelo-depleted P. falciparum murine model. Among several triazole sulphonamide derivatives 211 (Fig. 42) , compounds 211a and 211b with IC 50 of 0.023 and 0.025 μg/mL, respectively against chloroquine resistant strain of P. falciparum, were comparable to chloroquine (IC 50 : 0.020 μg/mL) and 10-fold more potent than quinine (IC 50 : 0.268 μg/mL) [187] . Among the synthesized triazole Schiff bases 212 (Fig. 42) , compounds 212a-c (IC 50 : 0.230-0.282 μM) displayed higher antimalarial potency against P. falciparum than pyrimethamine (IC 50 : 1.005 μM) [188] . Further in vitro enzyme inhibition study indicated that 212b with IC 50 of 0.0259 μM was found to be most potent DHFR inhibitor as compared to chloroquine (IC 50 : 0.0301 μM) and pyrimethamine (IC 50 : 0.1007 μM). Dihydroorotate dehydrogenase (DHODH), enzyme in the de novo biosynthetic pathway, has emerged as promising target for development of novel antimalarial agents. Phillips and his co-workers [189] [190] [191] [192] [193] falciparum in SCID mouse model with ED 90 value of 8.1 mg/kg [190] . Subsequent optimization highlighted that compound 213b with both meta-fluorines on the aniline ring and fluoroethyl at C-2 of the triazoloprymidine ring have poor species selectivity toward DHODH [191] . Further exploration of antimalatial drug candidate 213a by replacing SF 5 -phenyl moiety with a series of CF 3 -pyridinyls identified a promising compound 213c (DSM421, Fig. 42 ) with more enhanced drug-like properties which displayed 2-fold higher activity with IC 50 of 0.053 μM on PfDHODH than for P. vivax DHODH (IC 50 : 0.094 μM) [193] . Notably, it also showed equivalent activity against field isolates of P. falciparum and P. vivax. Antimalarial evaluation of twenty six [1, 2, 4] [195, 196] . Franklim et al designed and synthesized 1,2,4-triazole derivatives by optimization of previously reported N 4 -cyclohexyl-1,2,4-triazole 215 having anti-T. cruzi activity [197] . The study revealed that S-alkylated-triazoles 216a-c (Fig. 43) forms, respectively) [198] . Silva et al synthesized 1,2,4-triazole derivatives 217 (Fig. 43 ) employing the bioisosterism and molecular hybridization approaches as nitrofurazone analogues, which have shown selectivity against intracellular amastigotes of T. cruzi Y strain [199] . Compound 217a with IC 50 of 5.53 µM and SI >36 was equipotent to drug benznidazole, but exhibited lower efficacy. Furthermore, 217a was found to be 26 fold more potent than analogue 217b, highlighting the impact of nitro group on antitrypanosomal activity. Papadopoulou et al reported antichagasic activity of 3-nitro-1H-1,2,4-triazolebased aliphatic and aromatic amines [200] [201] [202] . donovani. The SAR of 3-nitrotriazole-based heteroarylamides/ sulfonamides revealed that chlorinated thiophene sulfonamides and benzothiophene amides 230 (Fig. 43) were the most active antichagasic compounds, displaying up to 14 fold higher potency than the standard [204] . Fig. 44 ) that does not inhibit the human proteasome [208] . It also exhibited in vivo efficacy which cleared parasites in mouse models of leishmaniasis, Chagas disease and HAT. Inhibition of the proteasome chymotrypsin-like activity is demonstrated as primary mechanism of parasite growth inhibition by GNF6702. Compounds 234 (GNF6702) and its analogue 235 (NITD689, Fig. 44 ) showed in vitro concentration-time dependent trypanocidal activity with favourable in vivo pharmacokinetics and significant brain penetration [209] . Importantly, both compounds, act by inhibiting chymotrypsin activity of the 20S proteasome in T. brucei, are efficacious for achieving complete cure in HAT hemolymphatic (1 and 10 mg/kg, respectively, once daily, for four days) and meningoencephalic mouse models (at 30 and 60 mg/kg dose, respectively). A set of hydrazone derivatives of 1,2,4-triazole 241 (Fig. 46) was evaluated for radical scavenging and anti-inflammatory activities in vitro and in vivo by Khan et al [213] . The most potent compound 241a with 64.44% inhibition of edema and a potency of 0.92 at 20 mg/kg body weight after 5h of inducing inflammation was comparable to reference indomethacin (potency 1.00). Docking study revealed that compound 241a occupied celecoxib binding site in COX with high affinity (Fig. 46) and binding free energy of -10.5 and -11.2 kcal/mol for COX-1 and COX-2, respectively. Interestingly, NO-triazole hybrids 244 (Fig. 46) were found to be more potent anti-inflammatory agents than the corresponding ketone intermediates [216] . Among the synthesized oximes, compound 244a exhibited high anti-inflammatory activity (79%) after 4 h and lower ulcerogenicity (ulcer index 0.25). In another study, quinoline incorporating 1,2,4-triazole/oxime hybrids 245a-c (Fig. 46 ) displayed significant antiinflammatory activity compared to indomethacin with % edema inhibition of 100%, 101% and 111%, respectively [217]. indole 246 (Fig. 46) for their in vitro anti-inflammatory activity [218] . Compound 246a was found to be the most potent inhibitors of cytokine Eselectin and COX-2 enzyme (IC 50 : 0.98 μM and SI: 8.05). Biological screening of Schiff and Mannich bases derivatives of 1,2,4-triazoles 247 (Fig. 46) at a dose of 20 mg/kg in rats by Gowda et al revealed that compounds 247c and 247d showed good anti-inflammatory activity compared to indomethacin whereas compounds 247a, 247b and 247d showed significant analgesic effects [219] . Receptor interacting protein 1 (RIP1) kinase is critical regulator of necroptosis and inflammation. DNA-encoded library (DELs) screening and lead optimization has resulted in identification of clinical candidate GSK2982772 (248, Fig. 46 ) as first-in-class RIP1 inhibitor which is currently in pre-clinical trials for inflammatory diseases, including psoriasis, rheumatoid arthritis, and ulcerative colitis [220] . Two series of 1,2,4-triazole based benzothiazole derivatives 249 and 250 (Fig. 46) were synthesized and evaluated for their in vitro anti-inflammatory activity and p38α MAP kinase inhibition by Tariq et al [221, 222] . Among the selected compounds for in vivo evaluation, compounds 249a and 250a emerged as the most potent compound with edema inhibition of 84.43% and 85.31%, respectively. Paprocka et al reported that 1,2,4-triazole derivatives 251 (Fig. 46) containing methacrylic acid moiety exerted anti-inflammatory activity via modulation of monocytes activation [223] . A novel series of celecoxib derivatives with triazole moiety have been screened for their anti-inflammatory potential by CPE test by Mustafa et al and most of the them showed higher activity compared to Celecoxib [224] . The pharmacology screening a series of 6-substituted thiazolo[3,2-b]-1,2,4triazole-5(6H)-one derivatives of ibuprofen revealed that compounds 252a-c (Fig. 47) displayed potential in vivo analgesic/anti-inflammatory activity without a gastrointestinal side effect [225] . (Fig. 47) and screened for their anti-inflammatory activity by xylene-induced ear-edema test [228] . The study indicated that the most potent compound 257a with 50.48% activity at 30 min after intraperitoneal administration was more active than the reference drug indomethacin. Shehry et al synthesized of a series of 3-(2,4-dichlorophenoxy)methyl)-1,2,4triazolo (thiadiazoles and thiadiazines) and screened for their anti-inflammatory activity [229] . Among them, compounds 258-261 (Fig. 47) showed 36-56% anti-inflammatory activity comparable to the standard indomethacin. ( Fig. 47 ) screened for their anti-inflammatory potential in the CPE test at 10 mg/kg oral dose, compounds 262a (82.24%) and 262b (83.06%) exhibited potent anti-inflammatory activity than indomethacin (81.55%) [230] . SAR studies on [1, 2, 4] triazolo [4,3-a] [1, 8] naphthyridine scaffold were conducted by Bracci et al with the objective of improving potency for anti-inflammatory and/or analgesic activities [231] . Results revealed that compound 263b-f (Fig. 47 ) exhibited good anti-inflammatory activity ranging from 34% to 80% and compound 263c was found to be more potent and effective than the parent compound 263a [232] . Whereas compounds 264a-c (Fig. 47) were endowed with prevalent analgesic activity (74%-96% inhibition in the writhing test in mice, P < 0.01, 50 mg/kg dose) frequently associated with sedative effects. Guirado et al synthesized a series of triazolo[4,3-a]quinoxalines 265 (Fig. 47 ) and evaluated for their anti-inflammatory activity as inhibitors of the pro-inflammatory cytokines TNF-α and IL-6 [233] . Results revealed that compound 265c was found to be the most potent while compounds 265a-d exhibited good levels of inhibition against both cytokines. Liu et al synthesized a series of triazolo[3,4-a]phthalazine-3-carboxamide derivatives 266 (Fig. 47) as potent anti-inflammatory agents, which acted on tumor necrosis factor (TNF-α) as inhibitors of NF-κB activation [234] . Moreover, compound 266a exhibited excellent anti-inflammatory activity with 58.19% inhibition at 50 mg/kg (i.p.) against xylene-induced ear edema, with equal efficacy as the standard drug indomethacin (100 mg/kg i.p; 59.21% inhibition). Several thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen 267 (Fig. 47) exhibited significant analgesic and anti-inflammatory activities with low gastric risk [235] . Moreover, compound 267a was found to be the most selective COX-2 inhibitor with IC 50 of 20.5 μM and SI > 4.87). Some other 1,2,4-triazole derivatives have been synthesized and screened for antiinflammatory and analgesic activities [236] [237] [238] . Aggarwal et al reported 1,2,4-triazolo[4,3-a]quinoxaline derivatives 268 and 1,2,4-triazolo[4,3-a]quinoxalin-4(5H)-ones 269 (Fig. 48) as effective DNA photocleavers [239, 240] . Among all the synthesized molecules, compound 268c and 269k showed significant photocleavage of supercoiled plasmid ΦX174 and pMaxGFP, respectively under UV irradiation at λ max 312 nm. DNA cleaving efficiency of 269 was found to be dependent on its structure, concentration, and strictly on photoirradiation time. A series of triazolopyrimidine hybrids was designed and synthesized as multifunctional anti-Alzheimer agents by Jameel et al [242, 243] . Compounds 271a and 271b (Fig. 48 ) exhibited more potent acetylcholinesterase (AChE) inhibitory potential with IC 50 values 0.065 and 0.092 μM, respectively and high selectivity for AChE over BuChE by ~28 fold. Notably, these compounds exhibited better Cu 2+ -induced Aβ1-42 aggregation inhibitory potency. inhibitors [244] . The study revealed that compounds 272a and 272b with EC 50 values of 18.6 and 57.1 μM, respectively, showed better bronchodilator activity than the reference theophylline (EC 50 : 425 μM). Contemporary medicinal chemistry faces many challenges from several directions, including the need for both potency and specificity of any therapeutic agent. Therefore, in the present perspective, 1,2,4-triazole with broad spectrum biological profile have (c) CH 2 Fig. 17. 1,2 ,4-Triazole derivatives as methionine aminopeptidase type II inhibitors. ; • 1,2,4-Triazole derivatives possess promising potential in drug designing and development. • Advances in biological activities in the last decade of 1,2,4-triazole as privileged structure. • Plausible mode of action and biomolecular targets for therapeutic potential. • Emphasis on structure-activity relationship. Coumarin-triazole hybrids and their biological activities Tautomerism of 1,2,3-and 1,2,4-triazole in the gas phase and in aqueous solution: A combined ab Initio quantum mechanics and free energy perturbation study Triazole antifungals: A review Recent researches in triazole compounds as medicinal drugs A century of fungicide evolution Synthesis and biological evaluation of 1,2,4-triazole derivatives as potential neuroprotectant against ischemic brain injury Insights on the antioxidant potential of 1, 2, 4-triazoles: Synthesis, screening and QSAR studies Triazole derivatives and their antiplasmodial and antimalarial activities Green synthesis, antileishmanial activity evaluation, and in silico studies of new amino acid-coupled 1,2,4-triazoles Synthesis of some new 1,2,4-triazole derivatives starting from 3-(4-chlorophenyl)-5-(4-methoxybenzyl)-4H-1,2,4-triazol with anti-lipase and anti-urease activities Synthesis and biological evaluation of some novel Asymmetric synthesis of novel triazole derivatives and their in vitro antiviral activity and mechanism of action Plech, 1,2,4-Triazole-based anticonvulsant agents with additional ROS scavenging activity are effective in a model of pharmacoresistant epilepsy Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors 3-Phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: High-affinity γ-aminobutyric acid-A benzodiazepine receptor ligands with α2, α3, and α5-subtype binding selectivity over α1 Poly(1-vinyl-1,2,4-triazolium) poly(ionic liquid)s: Synthesis and the unique behavior in loading metal ions A Review on 1,2,4-triazole derivatives as corrosion inhibitors Coordination polymers containing 1,3-phenylenebis-((1H-1,2,4-triazol-1-yl)methanone) ligand: Synthesis and ε-caprolactone polymerization behaviour Optical waveguides from 4-aryl-4H-1,2,4-triazole-based supramolecular structures Bhagavath, 1,2,3/1,2,4-Triazole containing liquid crystalline materials: An up-to-date review of their synthetic design and mesomorphic behaviour Novel conformationally restricted triazole derivatives with potent antifungal activity Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14α-demethylase Design, synthesis, and antifungal activities of novel triazole derivatives containing the benzyl group Sun, Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives Synthesis, in vitro evaluation and molecular docking studies of new triazole derivatives as antifungal agents Design and synthesis of novel triazole antifungal derivatives by structure-based bioisosterism Sheng, Design, synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxypropylamino side chains Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement Triazole derivatives with improved in vitro antifungal activity over azole drugs Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates Synthesis and evaluation of novel azoles as potent antifungal agents Design, synthesis, and in vitro evaluation of novel antifungal triazoles Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives Synthesis and activity of novel indole linked triazole derivatives as antifungal agents Design, synthesis, and structure-activity relationship studies of novel fused heterocycleslinked triazoles with good activity and water solubility Novel alkylated azoles as potent antifungals Novel carbazole-triazole conjugates as DNA-targeting membrane active potentiators against clinical isolated fungi Antifungal activity, mode of action variability, and subcellular distribution of coumarin-based antifungal azoles Synthesis and antimicrobical evaluation of a novel class of 1,3,4-thiadiazole: Derivatives bearing 1,2,4-triazolo[1,5-a]pyrimidine moiety The synthesis, antifungal and apoptotic effects of triazole-oxadiazoles against Candida species Access to a new class of biologically active quinoline based 1,2,4-triazoles Synthesis and antifungal activity of novel myrtenal-based 4-methyl-1,2,4-triazole-thioethers Design, synthesis, biological activities and DFT calculation of novel 1,2,4-triazole Schiff base derivatives Synthesis of novel sulfonamide-1,2,4-triazoles, 1,3,4-thiadiazoles and 1,3,4-oxadiazoles, as potential antibacterial and antifungal agents. Biological evaluation and conformational analysis studies Synthesis, antifungal and antibacterial activity for novel amide derivatives containing a triazole moiety Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents Synthesis and in vitro activity of 1,2,4-triazole-ciprofloxacin hybrids against drug-susceptible and drug-resistant bacteria Search for factors affecting antibacterial activity and toxicity of 1,2,4-triazole-ciprofloxacin hybrids Piperazine-azole-fluoroquinolone hybrids: Conventional and microwave irradiated synthesis, biological activity screening and molecular docking studies Synthesis and biological evaluation of a class of quinolone triazoles as potential antimicrobial agents and their interactions with calf thymus DNA Synthesis and antibacterial activity of novel Synthesis, antimicrobial evaluation and QSAR analysis of novel nalidixic acid based 1,2,4-triazole derivatives Synthesis, antimicrobial activity and molecular modeling study of 3-(5-amino-(2H)-1,2,4-triazol-3-yl]-naphthyridinones as potential DNA-gyrase inhibitors Synthesis and biological evaluation of dihydroindeno and indeno Facile synthesis, cytotoxic and antimicrobial activity studies of a new group of 6-aryl-3 Synthesis and antibacterial activity of N-substituted Abu-zied, Synthesis of novel 1,2,4-triazolopyrimidines and their evaluation as antimicrobial agents 3-a]pyridine moiety Design, synthesis and antimicrobial activities of thiouracil derivatives containing triazolo-thiadiazole as SecA inhibitors New heterocyclic compounds from 1,2,4-triazole and 1,3,4-thiadiazole class bearing diphenylsulfone moieties. Synthesis, characterization and antimicrobial activity evaluation Synthesis and antimicrobial activities of some novel 1,2,4-triazole derivatives (2-Aminothiazol-4-yl)-4-phenyl-4H-1,2,4-triazole-3-thiols as a new class of DHFR inhibitors: Synthesis, biological evaluation and molecular modeling study Synthesis of novel 1,2,4-triazole derivatives containing the quinazolinylpiperidinyl moiety and N-(substituted phenyl)acetamide group as efficient bactericides against the phytopathogenic bacterium Xanthomonas oryzae pv. oryzae Design, synthesis and evaluation of triazole-pyrimidine analogues as SecA inhibitors Synthesis and evaluation of a class of new coumarin triazole derivatives as potential antimicrobial agents Synthesis and biological activities of novel aminederived bis-azoles as potential antibacterial and antifungal agents Potential antimicrobial isopropanol-conjugated carbazole azoles as dual targeting inhibitors of Enterococcus faecalis Synthesis and biological evaluation of α-triazolyl chalcones as a new type of potential antimicrobial agents and their interaction with calf thymus DNA and human serum albumin Current targets for anticancer drug discovery Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors Synthesis, molecular modeling, in vivo study, and anticancer activity of 1,2,4-triazole containing hydrazide-hydrazones derived from (S)-naproxen New coumarin derivatives as anti-breast and anti-cervical cancer agents targeting VEGFR-2 and p38α MAPK Design and synthesis of novel 2-(4-(2-(dimethylamino)ethyl)-4H-1,2,4-triazol-3-yl)pyridines as potential antitumor agents Discovery of novel diaryl urea derivatives bearing a triazole moiety as potential antitumor agents Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors Synthesis, antitumor evaluation and molecular docking studies of The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer )methyl)quinoline as a highly potent and selective c-Met inhibitor ]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a potent and selective inhibitor of MET with high unbound target coverage and robust in vivo antitumor activity Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors Discovery of imidazopyridine derivatives as novel c-Met kinase inhibitors: Synthesis, SAR study, and biological activity Identification of 1,2,4-triazoles as new thymidine phosphorylase inhibitors: Future anti-tumor drugs dione and its 5-thioxo analogues on anti-thymidine phosphorylase and associated antiangiogenic activities Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking Indomethacin based new triazolothiadiazine derivatives: Synthesis, evaluation of their anticancer effects on T98 human glioma cell line related to COX-2 inhibition and docking studies Benzenesulfonamide bearing 1,2,4-triazole scaffolds as potent inhibitors of tumor associated carbonic anhydrase isoforms hCA IX and hCA XII Synthesis and aromatase inhibitory evaluation of 4-N-nitrophenyl substituted amino-4H-1, 2, 4-triazole derivatives Synthesis, structureactivity relationship studies and biological characterization of new Design, synthesis, crystallographic studies, and preliminary biological appraisal of new substituted triazolo[4,3-b]pyridazin-8-amine derivatives as tankyrase inhibitors Triazolopyrimidines are microtubule-stabilizing agents that bind the vinca inhibitor site of tubulin Design, synthesis and cytotoxic evaluation of novel chalcone derivatives bearing triazolo[4,3-a]-quinoxaline moieties as potent anticancer agents with dual EGFR kinase and tubulin polymerization inhibitory effects Synthesis of triazoloquinazolinone based compounds as tubulin polymerization inhibitors and vascular disrupting agents Novel 1,2,4-triazole derivatives as potential anticancer agents: Design, synthesis, molecular docking and mechanistic studies Discovery and optimization of 3,4,5-trimethoxyphenyl substituted triazolylthioacetamides as potent tubulin polymerization inhibitors Synthesis, antiproliferative, anti-tubulin activity, and docking study of new 1,2,4-triazoles as potential combretastatin analogues Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues 3-Aryl/heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization Synthesis and anticancer activity evaluation of a series of Synthesis, antitumor evaluation and 3D-QSAR studies of ]pyrimidine derivatives that induce apoptosis through G1 cell-cycle arrest f]pteridinone derivative as potent antitumor agents Synthesis of novel chromene derivatives of expected antitumor activity El-Dash, Synthesis, characterization and cytotoxicity of substituted Synthesis and bioevaluation of 6-chloropyridazin-3-yl hydrazones and 6-chloro-3-substituted Design, synthesis and biological evaluation of novel 1,2,4-triazolo and 1,2,4-triazino[4,3-a]quinoxalines as potential anticancer and antimicrobial agents Regioselective synthesis of 6-aryl-benzo Synthesis and anticancer activities of novel 1 Benzimidazole clubbed with triazolo-thiadiazoles and triazolo-thiadiazines new anticancer agents Gong, Design, synthesis and biological evaluation of novel 2,4-diaminopyrimidine derivatives as potent antitumor agents Design, synthesis and biological evaluation of novel 1 Synthesis and cytotoxicity of 3,4-disubstituted-5-(3,4,5-trimethoxyphenyl)-4H-1,2,4-triazoles and novel 5,6-dihydro Synthesis of novel 1,2,4-triazoles, triazolothiadiazines and triazolothiadiazoles as potential anticancer agents Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells Onepot synthesis of novel isoindoline-1,3-dione derivatives bearing 1,2,4-triazole moiety and their preliminary biological evaluation Design, synthesis and biological evaluation of novel 3-alkylsulfanyl-4-amino-1,2,4-triazole derivatives Synthesis and biological evaluation of disulfides bearing 1,2,4-triazole moiety as antiproliferative agents Synthesis of 1,2,4-triazole-linked urea/thiourea conjugates as cytotoxic and apoptosis inducing agents Synthesis and antiproliferative activity of some new thieno[2,3-d]pyrimidin-4(3H)-ones containing 1,2,4-triazole and 1,3,4-thiadiazole moiety Design, selective alkylation and X-ray crystal structure determination of dihydro-indolyl-1,2,4-triazole-3-thione and its 3-benzylsulfanyl analogue as potent anticancer agents Efficient synthesis of some new 1,3,4-thiadiazoles and 1,2,4-triazoles linked to pyrazolylcoumarin ring system as potent 5α-reductase inhibitors Design, synthesis, and biological evaluation of coumarin-triazole hybrid molecules as potential antitumor and pancreatic lipase agents Microwave-expedited green synthesis, photophysical, computational studies of coumarin-3-yl-thiazol-3-yl-1,2,4-triazolin-3-ones and their anticancer activity Synthesis and biological evaluation of 4-(1H-1,2,4-triazol-1-yl)benzoic acid hybrids as anticancer agents (4H)-ones and their derivatives Novel agonists of benzodiazepine receptors: design, synthesis, binding assay and pharmacological evaluation of 1,2,4-triazolo[1,5-a]pyrimidinone and 3-amino-1,2,4-triazole derivatives (4H)-one derivatives as positive modulators of GABA A1 receptor with potent anticonvulsant activity and low toxicity Design and synthesis of 10-alkoxy-5,6-dihydro-triazolo Synthesis and evaluation of the anticonvulsant activity of 8-alkoxy-4,5-dihydrobenzo Synthesis and anticonvulsant evaluation of some new 6-(substituted-phenyl)thiazolo Synthesis and anticonvulsant activity evaluation of 7-alkoxy-2,4-dihydro-1H ]thiazin-1-ones in various murine experimental seizure models Synthesis and anticonvulsant activity evaluation of 4-phenyl Design, synthesis, and evaluation of the anticonvulsant and antidepressant activities of pyrido[2,3-d]pyrimidine derivatives Synthesis and anticonvulsant activity of a new alkoxy Synthesis and anticonvulsant activity of new phenytoin derivatives Studies on the anticonvulsant activity and influence on GABAergic neurotransmission of 1,2,4-triazole-3-thione-based compounds Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles Studies on the anticonvulsant activity of 4-alkyl-1,2,4-triazole-3-thiones and their effect on GABAergic system Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones Synthesis and anticonvulsant activity of novel purine derivatives New (arylalkyl)azole derivatives showing anticonvulsant effects could have VGSC and/ or GABA A R affinity according to molecular modeling studies Design, synthesis, anticonvulsant activity, and pharmacophore study of new 1,5-diaryl-1H-1,2,4-triazole-3-carboxamide derivatives Synthesis and biological evaluation of novel benzothiazole derivatives as potential anticonvulsant agents Design, synthesis and 3D-QSAR studies of new diphenylamine containing 1,2,4-triazoles as potential antitubercular agents Some novel Schiff bases of [1,2,4]triazole bearing haloarene moiety synthesis and evaluation of antituberculosis propertiesand neutrophil function test Development of 3,5-dinitrophenyl-containing 1,2,4-triazoles and their trifluoromethyl analogues as highly efficient antitubercular agents inhibiting decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis Triazolophthalazines: Easily accessible compounds with potent antitubercular activity The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents Synthesis of some novel 2-substituted-5-[isopropylthiazole] clubbed 1, 2, 4-triazole and 1, 3, 4-oxadiazoles as potential antimicrobial and antitubercular agents Synthesis and pharmacological evaluation of clubbed isopropylthiazole derived triazolothiadiazoles, triazolothiadiazines and mannich bases as potential antimicrobial and antitubercular agents Synthesis and antimycobacterial activity of azetidine-, quinazoline-, and triazolo-thiadiazole-containing pyrazines ]thiadiazoles as inhibitors of Mtb shikimate dehydrogenase for the development of novel antitubercular agents Preliminary SAR and biological evaluation of antitubercular triazolothiadiazine derivatives against drug-susceptible and drug-resistant Mtb strains IMB-SD62, a triazolothiadiazoles derivative with promising action against tuberculosis Nitrotriazole and imidazole-based amides and sulfonamides as antitubercular agents The antitubercular activity of various nitro(triazole/imidazole)-based compounds Click chemistry based regioselective one-pot synthesis of coumarin-3-yl-methyl-1,2,3-triazolyl-1,2,4-triazol-3(4H)-ones as newer potent antitubercular agents Synthesis and antimycobacterial activities of some new thiazolylhydrazone derivatives Novel 4H-1,2,4-triazol-3-yl cycloalkanols as potent antitubercular agents Ultrasonicationionic liquid synergy for the synthesis of new potent antituberculosis 1,2,4-triazol-1-yl-pyrazole based spirooxindolopyrrolizidines Synthesis, biological evaluation and in silico studies of 1,2,4-triazole and 1,3,4-thiadiazole derivatives as antiherpetic agents Enterovirus inhibitory activity of C-8-tert-butyl substituted 4-aryl-6 Synthesis, characterization, and biological evaluation of some novel quinoxaline derivatives as antiviral agents A broad anti-influenza hybrid small molecule that potently disrupts the interaction of polymerase acidic protein-basic protein 1 (PAPB1) subunits Altaher, Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-Narylacetamides as potent HIV-1 inhibitors Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs Microwave assisted synthesis of pyrimidines in ionic liquid and their potency as non-classical malarial antifolates Microwave assisted one-pot synthetic route to imidazo[1,2-a]pyrimidine derivatives of imidazo/triazole clubbed pyrazole and their pharmacological screening Anti-plasmodium activity of imidazolium and triazolium salts Carbamoyl triazoles, known serine protease inhibitors, are a potent new class of antimalarials Cyclopropyl carboxamides: A new oral antimalarial series derived from the tres cantos anti-malarial set (TCAMS) Synthesis of novel sulfonamides as potential antibacterial, antifungal and antimalarial agents 1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors Tetrahydro-2-naphthyl and 2-indanyl triazolopyrimidines targeting Plasmodium falciparum dihydroorotate dehydrogenase display potent and selective antimalarial activity A triazolopyrimidine based dihydroorotate dehydrogenase inhibitor with improved drug-like properties for treatment and prevention of malaria The development of novel compounds against malaria: Quinolines, triazolpyridines, pyrazolopyridines and pyrazolopyrimidines In vitro antileishmanial activity of ravuconazole, a triazole antifungal drug, as a potential treatment for leishmaniasis vitro activity of the antifungal azoles itraconazole and posaconazole against Leishmania amazonensis Design, synthesis and trypanocidal evaluation of novel 1,2,4-triazoles-3-thiones derived from natural piperine Design, synthesis, trypanocidal activity, and studies on human albumin interaction of novel S-alkyl-1,2,4-triazoles Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents Novel nitro(triazole/imidazole)-based heteroarylamides/sulphonamides as potential antitrypanosomal agents Discovery of potent nitrotriazolebased antitrypanosomal agents: in vitro and in vivo evaluation Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness Anti-trypanosomal proteasome inhibitors cure hemolymphatic and meningoencephalic murine infection models of african trypanosomiasis Antileishmanial potential of fused 5-(pyrazin-2-yl)-4H-1,2,4-triazole-3-thiols: Synthesis, biological evaluations and computational studies Unraveling the alkaline phosphatase inhibition, anticancer, and antileishmanial potential of coumarintriazolothiadiazine hybrids: Design, synthesis, and molecular docking analysis Antileishmanial activity study and theoretical calculations for 4-amino-1,2,4-triazole derivatives Synthesis, characterization and anti-inflammatory activity evaluation of 1,2,4-triazole and its derivatives as a potential scaffold for the synthesis of drugs against prostaglandin-endoperoxide synthase 1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: Synthesis, molecular modeling, evaluation of their antiinflammatory activity and ulcerogenicity Novel 1-[4-(aminosulfonyl)phenyl]-1H-1,2,4-triazole derivatives with remarkable selective COX-2 inhibition: Design, synthesis, molecular docking, anti-inflammatory and ulcerogenicity studies 1,2,4-Triazole/oxime hybrids as new strategy for nitric oxide donors: Synthesis, antiinflammatory, ulceroginicity and antiproliferative activities Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study Synthesis, characterization and pharmacological activity of 4-{[1-substituted aminomethyl-4-arylideneamino-5-sulfanyl-4,5-dihydro-1H-1,2,4-triazol-3-yl]methyl}-2H-1,4-benzothiazin-3(4H)-ones Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases Amir, 1,2,4-Triazole-based benzothiazole/benzoxazole derivatives: Design, synthesis, p38α MAP kinase inhibition, anti-inflammatory activity and molecular docking studies Amir, Synthesis, p38α MAP kinase inhibition, antiinflammatory activity, and molecular docking studies of 1,2,4-triazole-based benzothiazole-2-amines Synthesis and anti-inflammatory activity of new 1,2,4-triazole derivatives An efficient method for the synthesis of novel derivatives 4-{5 Thiazolo[3,2-b]-1,2,4-triazole-5(6H)-one substituted with ibuprofen: Novel non-steroidal anti-inflammatory agents with favorable gastrointestinal tolerance El-Ashmawy, Design, synthesis and biological evaluation of some novel thienopyrimidines and fused thienopyrimidines as antiinflammatory agents ]pyrimidines as anti-inflammatory and analgesic agents (4H)-one derivatives and evaluation of their anti-inflammatory activity 4-dichlorophenoxy)methyl)-1, 2, 4-triazolo(thiadiazoles and thiadiazines) as antiinflammatory and molluscicidal agents Synthesis and anti-inflammatory activity of fused 1,2,4-triazolo ]naphthyridine-6-carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10H-pyrimido naphthyridine-6-carboxamide derivatives showing potent analgesic or antiinflammatory activity, respectively, and completely devoid of acute gastrolesivity Synthesis and biological evaluation of 4-alkoxy-6 Synthesis and antiinflammatory activity evaluation of a novel series of 6-phenoxy Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic/antiinflammatory properties: Synthesis, biological evaluation and molecular modeling studies Analgesic and anti-inflammatory potential of merged pharmacophore containing 1,2,4-triazoles and substituted benzyl groups via thio linkage Design and synthesis of 1,2,4-triazolo[3,2-b]-1,3,5-thiadiazine derivatives as a novel template for analgesic/anti-inflammatory activity Facile synthesis, characterization and pharmacological activities of 3,6-disubstituted 1 Copper(II) chloride mediated synthesis and DNA photocleavage activity of 1-aryl/heteroaryl-4-substituted-1,2,4-triazolo[4,3-a]quinoxalines Design, synthesis and photoinduced DNA cleavage studies of WS-10) that modulates ABCB1-mediated multidrug resistance (MDR) Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies pyrimidine derivatives as PDE 4B inhibitors endowed with bronchodilator activity Support of this research by D. A. V. College (Lahore), Ambala City is gratefully acknowledged. The authors confirm that this article content has no conflict of interest.